In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma

International Journal of Dermatology

Volumn 48, Issue 3, 2009, Pages 312-321

  De Giorgi, Vincenzo ^a   Salvini, Camilla ^a   Chiarugi, Alessandra ^a   Paglierani, Milena ^a   Maio, Vincenza ^a   Nicoletti, Paola ^a   Santucci, Marco ^a   Carli, Paolo ^a   Massi, Daniela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; IMIQUIMOD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; T6 ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CANCER MORPHOLOGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; EVENING DOSAGE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IN VIVO STUDY; INFLAMMATORY INFILTRATE; MACROPHAGE; MALE; NATURAL KILLER CELL; OPEN STUDY; PROTEIN EXPRESSION; SKIN BIOPSY;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTIGENS, CD3; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OINTMENTS; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 61349145684     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.03916.x     Document Type: Article

References (18)

1. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005;152:939-947.
2. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005;31:318-323.
3. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50:722-733.
4. Schiller M, Metze D, Luger TA, et al. Immune response modifiers - mode of action. Exp Dermatol 2006;15:331-341.
5. Schon MP, Schon M. The small-molecule immune response modifier imiquimod - its mode of action and clinical use in the treatment of skin cancer. Expert Opin Ther Targets 2006;10:69-76.
6. Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and small molecules by the immune response modifier imiquimod. J Natl Cancer Inst 2003;95:1138-1149.
7. Vidal D, Matias-Guiu X, Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 2004;29:518-525.
8. Vidal D, Matias-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol 2004;151:656-662.
9. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003;139:1325-1332.
10. Berman B, Sullivan T, De Araujo T, et al. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003;149(Suppl): 59-61.
11. Sullivan TP, Dearaujo T, Vincek V, et al. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg 2003;29:1181-1186.
12. Barnetson RS, Satchell A, Zhuang L, et al. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol 2004;29:639-643.
13. Dummer R, Urosevic M, Kepmf W, et.al. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol 2003;149:57-58.
14. Meyer T, Nindl I, Schmook T, et al. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol 2003;149:9-13.
15. Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005;97:1143-1153.
16. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114:135-141.
17. Wong DA, Bishop GA, Lowes MA, et al. Cytokine profiles in spontaneously regressing basal cell carcinomas. Br J Dermatol 2000;143:91-98.
18. Bekeredjian-Ding IB, Wagner M, Hornung V, et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005;174:4043-4050.